Like CLL and AML cells, ALL blasts are also often characterized by BCL-2 and BCL-XL over-expression, suggesting that VEN could also possess anti-leukemic potential in this entity. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.